SGLT2 Inhibitors in Heart Failure Management with Dr. John McMurray
Heart Failure Guidelines - Prof. John Mcmurray - 5th Annual ESMA Conference 2023Подробнее
SGLT2 inhibitors in heart failure: New analyses and recent updatesПодробнее
ESC TV Conversations - SGLT2 inhibitors – wonder drugs in Heart Failure and beyond?Подробнее
Prof. John McMurray - What have we learned from the SGLT2i trials in heart failure?Подробнее
Prof. John McMurray | Contraindications for EmpagliflozinПодробнее
Professor John McMurray - Heart failure: pharmacology that extends the limits!Подробнее
Heart Failure Management in India - From Bench to BedsideПодробнее
CSI WB 2023 - HF Summit - 23 Sep - Session 7 - Dr. John McMurrayПодробнее
CSI 2022 Talks on The DELIVER Trial by Prof. John McMurray, UKПодробнее
Dr John McMurray Compares EMPEROR-Reduced Findings with DAPA-HFПодробнее
Dr. McMurray discusses the DAPA-HF trial of dapagliflozin in systolic heart failureПодробнее
Dr John McMurray: The Next Step for SGLT 2 Inhibitors in Patients with HF Is ImplementationПодробнее
Results of DAPA-HF - Dr. John J McMurrayПодробнее
ALL ABOUT DAPAGLIFLOZIN DR JOHN MCMURRAY PI DAPAHF DARREN MCGUIRE PI DECLARE TIMI DR VIJAY V DR J SПодробнее
DAPA HF study resultsПодробнее
AHA 2019: DAPA-HF - Dr Harriette Van Spall & Prof John McMurrayПодробнее
current concepts in Heart Failure management dr Ajit Mullasari Dr C K ponde Dr John McMurrayПодробнее
Dr John McMurray: Dapagliflozin Excels as a Preventive and Established Treatment for Heart FailureПодробнее
Dr John McMurray Explains the Heart Failure Benefits of Dapagliflozin in Diabetics and Non-DiabeticsПодробнее
